Recently, Elon Musk claimed that Tesla is becoming known more as an Artificial Intelligence and Robotics company. The argument was put forth during Tesla's Q1 2021 Earnings call on April 26th. Tesla's name has been resonating as a leader in the electric vehicle and self-driving cars market. Nonetheless, the company was dragged into many controversies due to the car crashes involving Tesla and other growing complaints about the technical quality issues. The statement from Elon Musk came in the context of Tesla being able to develop a cutting-edge AI team and technology for its self-driving cars.

Elon Musk made the argument that Tesla is going to be known more as an artificial intelligence and robotic company. For a while now, Musk has been pushing this idea that investors shouldn't just see Tesla as an automaker and energy company, but as a group of startups. He argues that Tesla's service centers are a startup, Tesla's insurance company is a startup, Tesla's automation group is a startup, etc. In that vein, Musk now claims that artificial intelligence and robotics are going to be just as synonymous with Tesla as cars and energy. The CEO commented during a conference call discussing Tesla's Q1 2021 financial results: Although right now people think of Tesla as a car company or as an energy company. I think long term, people will think of Tesla as much as an AI robotics company as we are a car company or an energy company.

Tribyl (tri.bal), the premier Buyer Intelligence Cloud platform, announced the launch of its machine learning-based win-loss analysis product for B2B enterprises of all sizes. Product marketers rely on timely insights into why and how customers are buying to inform messaging and positioning. However, win-loss analysis is a 100% manual process today -- data collection is painful and costly, and limited to a small fraction of deals. Tribyl's product is a first-of-its-kind solution that uses machine learning to mine both unstructured and structured data, creating a single source of truth across all buying journeys and enabling go-to-market teams to make smarter and faster decisions. Per CSO Insights, dynamic customer journey alignment can unlock 15-20% higher revenue growth.

Robotic process automation has become buzzy in the last few months. New York-based UiPath is on course to launch an initial public offering after gaining an astounding valuation of $35 billion in February. Over in China, homegrown RPA startup Laiye is making waves as well. Laiye, which develops software to mimic mundane workplace tasks like keyboard strokes and mouse clicks, announced it has raised $50 million in a Series C round. The proceeds came about a year after the Beijing-based company pulled in the first tranche of its Series C round.

Ride-hailing company Lyft has sold off its autonomous vehicle unit to Toyota's Woven Planet Holdings subsidiary for $550 million, the latest in a string of acquisitions spurred by the cost and lengthy timelines to commercialize autonomous vehicle technology. Under the acquisition agreement announced Tuesday, Lyft's so-called Level 5 division will be folded into Woven Planet Holdings. Lyft will receive $550 million in cash, with $200 million paid upfront. The remaining $350 million will be made in payments over five years. About 300 people from Lyft Level 5 will be integrated into Woven Planet.

Lyft Inc. is selling its self-driving division to a unit of Toyota Motor Corp. for $550 million, a move the ride-hailing giant said will help it turn a profit sooner than previously expected. Woven Planet Holdings, a Toyota subsidiary focused on autonomous technology, will pay $200 million up front as part of the deal, Lyft said Monday. The remaining $350 million will be paid in cash over a five-year-period. Lyft's departure from building self-driving cars follows rival Uber Technologies Inc.'s decision to shed its autonomous-driving division in December. The money-losing companies overhauled their businesses during the coronavirus pandemic and pledged to scale back on costly ventures as the health crisis crushed their core rides operations.

Let me start with a few keywords that should grab the attention of any potential investor: artificial intelligence (AI), deep learning, augmented reality, and accelerated computing. With technology advancements in these areas, computers are learning to write their own software, images are clearer, and the medical world is moving like the Millennium Falcon with Han Solo at the helm. When we take a look at how these areas are shaping our world, there's one name that is consistently at or near the top: NVIDIA (NASDAQ:NVDA). As a leader in innovative tech, from its GPUs that power gaming, enterprise graphics, and datacenters, to Jetson-like autonomous vehicles, the company has a hand in most things AI-related. But, did you know that NVIDIA's AI advancements also play an enormous part in the evolving healthcare industry?

Shukran Best Kebab – the finest Turkish restaurant in the Seven Sisters area of north London, according to some people (although it is surrounded by fierce rivals to the throne) – joined Deliveroo two years ago, and back then it seemed like a no-brainer. "Life as a small, independent restaurant is hard and the profit margins are slim," says Hüseyin Kurt, Shukran's owner. "We wanted more customers and money coming in and Deliveroo seemed to offer that. I didn't think there was a downside." Within a few days of signing a contract with the company, a shiny new tablet computer arrived on which orders placed via Deliveroo appeared out of the ether with a satisfying ping. The sense that something was wrong dawned gradually. Kurt, a gregarious, bearded man in his early 40s, who left his central Anatolian home town in 1995 and used his love of food to build a new life in the UK, ran the numbers: with Deliveroo's commission amounting to 35% plus VAT on every order, he was forced to increase his prices to avoid losing money on each sale.

Enterprise analytics company Clarify Health has secured $115 million in series C funding to scale its self-service healthcare analytics cloud and business software. Clarify Health combines longitudinal data for more than 300 million "unique patient lives" from government and commercial claims, electronic health records (EHRs) and prescriptions, according to the company. These data can help healthcare professionals manage population health and commercialize pharmaceutical and biotechnology products. "By linking CMS claims data with commercial claims, EHR, prescription and socioeconomic data, our models are trained on large cohorts and a more complete picture of each patient's longitudinal healthcare journey," Clarify Health CEO Jean Drouin, M.D., told Fierce Healthcare. The San Francisco-based company was launched in 2015 and has raised $178 million to date, according to Crunchbase.

Forecasts by Application (Drug Discovery, Precision Medicine, Medical Imaging & Diagnostics, Research), by Technology (Machine Learning, Other Technologies), by Offering (Hardware, Software, Services), by Deployment (Cloud, On-Premises) AND Regional and Leading National Market Analysis PLUS Analysis of Leading AI Companies AND COVID-19 Recovery ScenariosNew York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Artificial Intelligence (AI) in Pharmaceutical Market Report 2021-2031" - https://www.reportlinker.com/p06061831/?utm_source=GNW How Adoption of Artificial Intelligence Impacting Pharmaceutical Industry? The global pharmaceuticals industry is in the throes of transition, both clinical trials and regulatory approvals have been challenged by the proliferation of specialized drugs catering to smaller patient groups. In order to boost results in drug discovery, clinical trials, and research and development, the pharmaceutical and life sciences companies are switching to robotic process control, artificial intelligence and machine learning. All these factors are anticipated to propel demand for artificial intelligence in pharmaceutical across the globe. Artificial Intelligence Anticipated to Revolutionize Several Aspects of Pharmaceutical Industry The way drugs are made, prescribed and ingested today will be standardized by artificial intelligence. Many facets of the pharmaceuticals and life sciences industry will also be revolutionized but will not heal sickness or replace physicians. Understanding the main aim of artificial intelligence, which is to improve human capability and accomplishment instead of challenging it, would dispel much of the technology’s concerns and put out its excellent ability to serve humanity. Which Factors are Fueling AI in Pharmaceuticals Industry Growth? . Growing Complexity of Modern Pharmacology . Growing Demand for Viable Therapeutic Candidates . Improves Overall R&D Productivity . Concerns Associated with Rising Capital Requirements in Drug Discovery . Increasing Awareness Related to Artificial Intelligence Among Pharmaceutical Manufacturers Which Factors are Restraining Growth? . Lack of Skilled Professionals . Limited Availability of Datasets UNIQUE COVID-19 VARIATIONS- only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop - no matter how COVID-19 affects the economy. To access the data contained in this document please email contactus@visiongain.com How do prominent players strengthen their position throughout the world? You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks. Discover how to stay ahead Our 350+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AI in Pharmaceuticals Market. See how to exploit the opportunities. Forecasts to 2031 and other analyses reveal the commercial prospects . In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares. . You find original analyses, with business outlooks and developments. . Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, PEST Analysis, Porter’s Analysis, product profiles and commercial developments. Discover sales predictions for the world market and submarkets Application . Drug Discovery . Precision Medicine . Medical Imaging & Diagnostics . Research Technology . Machine Learning . Other Technologies Offering . Hardware . Software . Services Deployment . Cloud . On-Premises In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 13 leading national markets: By Region (Segmental Breakdown for All the Regions) . North America - U.S. - Canada . Europe - Germany - France - UK - Italy - Spain - Rest of Europe . Asia Pacific - China - Japan - India - Rest of Asia Pacific . RoW Need industry data? Please contact us today. Leading companies and the potential for market growth Overall world revenue for AI in Pharmaceuticals Market will surpass $xx billion in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. Prospects for established firms and those seeking to enter the market- including company profiles for 16 of the major companies involved in the AI in Pharmaceuticals Market. Some of the companies profiled in this report include are Microsoft Corporation, NVIDIA Corporation, IBM Corporation, Alphabet Inc., Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Insilico Medicine, BenevolentAI, Exscientia, Biosymetrics, Euretos, Insitro, Cyclica, Biovista, and OWKIN, INC. Key Questions Answered by this Report . What is the current size of the overall global AI in Pharmaceuticals market? How much will this market be worth from 2021 to 2031? . What are the main drivers and restraints that will shape the overall AI in Pharmaceuticals market over the next ten years? . What are the main segments within the overall AI in Pharmaceuticals market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why? . What factors will affect that industry and market over the next ten years? . What are the largest national markets for the world AI in Pharmaceuticals? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031? . How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031? . Which are the leading companies and what are their activities, results, developments, and prospects? . What are the main trends that will affect the world AI in Pharmaceuticals market between 2021 and 2031? . What are the main strengths, weaknesses, opportunities, and threats for the market? . How will the global AI in Pharmaceuticals market evolve over the forecasted period, 2021 to 2031? . How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth? Read the full report: https://www.reportlinker.com/p06061831/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001